-+ 0.00%
-+ 0.00%
-+ 0.00%

OS Therapies reports 71.2% 3-year survival in Phase 2b OST-HER2 metastatic osteosarcoma trial

PUBT·09/08/2026 10:02:35
Listen to the news
OS Therapies reports 71.2% 3-year survival in Phase 2b OST-HER2 metastatic osteosarcoma trial
  • OS Therapies reported interim 3-year survival findings from its Phase 2b OST-HER2 trial in fully resected pulmonary metastatic osteosarcoma.
  • Results have been presented in this interim analysis; final data analysis is expected within about a month.
  • Patients given OST-HER2 showed better long-term survival than a published historical comparison group, supporting the case for earlier market access.
  • Regulatory filings are targeted for late 2026, aiming for commercial availability in 2027, supported by accelerated or conditional pathways.
  • Received USD 3.15 million in UK VAT refunds; a further USD 7.2 million in VAT and R&D tax credits remains pending to fund a Phase 3 start.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609080600NEWSFILECNPR____20260908_313297_1) on September 08, 2026, and is solely responsible for the information contained therein.